This study investigates cancer anorexia-cachexia syndrome in patients with advanced pancreatic cancer. This condition is a common complication in advanced cancer patients, leading to reduced quality of life and poor treatment tolerance.
The study evaluates the safety and effectiveness of nanocrystalline megestrol acetate. It focuses on improvements in appetite, body weight, and quality of life for patients with advanced pancreatic cancer.
- Who can participate: Adults aged 18 to 75 years with advanced pancreatic cancer may participate. Key eligibility includes ECOG status, organ function requirements, and no prior systemic therapy for metastatic disease.
- Study details: Participants will take investigational nanocrystalline megestrol acetate with standard therapy or standard therapy alone. A placebo is not used in this study.
- Study timelines: The study will last 12 weeks.
How understandable was the trial content above?
Hard to understand
Easy to understand